TY - CHAP M1 - Book, Section TI - Pharmacotherapy for Gastric Acidity, Peptic Ulcers, and Gastroesophageal Reflux Disease A1 - Sharkey, Keith A. A1 - MacNaughton, Wallace K. A2 - Brunton, Laurence L. A2 - Hilal-Dandan, Randa A2 - Knollmann, Björn C. PY - 2017 T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e AB - Gastric acid and pepsin in the stomach normally do not produce damage or symptoms of acid-peptic diseases because of intrinsic defense mechanisms. The stomach is protected by a number of factors, collectively referred to as “mucosal defense,” many of which are stimulated by the local generation of PGs and NO. If these defenses are disrupted, a gastric or duodenal ulcer may form. The treatment and prevention of acid-related disorders are accomplished by decreasing gastric acidity and enhancing mucosal defense. The appreciation that an infectious agent, Helicobacter pylori, plays a key role in the pathogenesis of acid-peptic diseases revolutionized approaches to prevention and therapy of these common disorders. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1162543024 ER -